"Dr. John Seymour, a CLL researcher, shares an update about an ongoing trial using the Bcl-2 inhibitor ABT-199, which received a dose modification following safety concerns. Dr. Seymour explains Phase I trial data that demonstrates the therapy's balance of safety and efficacy as well its promising potential for combination with other agents.
Latest update on ABT-199 an interview of Dr Jo... - CLL Support
Latest update on ABT-199 an interview of Dr John Seymour Australian lead investigator by Patient Power
HAIRBEAR_UKFounder Admin
Written by
HAIRBEAR_UK
Founder Admin
To view profiles and participate in discussions please or .
2 Replies
•
I really enjoyed this down to earth video.Thanks
Not what you're looking for?
You may also like...
Dr. John Seymour on IgHV Mutational Status
with CLL/SLL will respond to different treatment options. Watch our interview with Dr. John Seymour...
Venetoclax (ABT-199) Receives Breakthrough Therapy Designation In Relapsed Or Refractory CLL In Previously Treated 17p deletion Patients
We are all in this together.
Brian
http://cllsociety.org
http://bkoffman.blogspot.com
Patient Power Presents – Dr. Matthew S Davids: Update on Treatment Studies in Richter’s
a short video of Dr. Matthews discussing recent data related to treatment studies for Richters...
Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD
ence-report-cll-btk-inhibitors-update?
Watch as Jennifer Brown, MD, PhD, Director, CLL Center, Dana
Your opportunity to suggest questions for Patient Power ASH 2013 Interviews
posted this request on the CLL ACOR List for questions to present to CLL experts he plans to...